Genmab A/S or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Genmab A/S or Sarepta Therapeutics, Inc.?

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, Genmab A/S and Sarepta Therapeutics, Inc. have shown contrasting trends in their SG&A expenditures.

From 2014 to 2023, Genmab A/S's SG&A costs surged by over 4,000%, reaching a peak in 2023. This dramatic increase reflects the company's aggressive expansion and investment in administrative capabilities. In contrast, Sarepta Therapeutics, Inc. maintained a more stable trajectory, with a modest increase of approximately 900% over the same period.

While Genmab's strategy might indicate a robust growth phase, Sarepta's steadier approach suggests a focus on cost control. Investors and stakeholders should consider these trends when evaluating the companies' financial health and strategic direction.